SEP 27, 2019 9:00 AM PDT

Investigating how Tpz-1 may be used as a novel therapeutic agent in the treatment of human hematologic cancers

Speaker
  • PhD Student, The University of Texas at El Paso (UTEP)
    Biography
      Jessica is a 2nd year PhD student at The University of Texas at El Paso. Jessica's research involves high-throughput screening of novel compounds for anticancer activity. She is currently focused on identifying the protein target of a potent compound that she found after screening more than 2,000 unique molecules. Most of Jessica's time in the lab is spent culturing various cancer and normal cell lines for use in cytotoxicity and mechanistic assays. The next step in her research is to analyze the transcriptome of cells treated with her compound to identify differentially expressed genes. Throughout the academic year, she also serves as a Teaching Assistant for undergraduate Biology lab courses. Outside of the lab, you can find Jessica working on science-themed stickers and stationery for her shop - Cell Kulture Co. Her mission is to encourage science-driven communication through art. She hopes that her colorful designs provide scientists an opportunity to engage in meaningful conversation about their research with non-experts. You can shop Jessica's current collection or inquire about custom orders at cellkultureco.com!

    Abstract
    DATE:  September 27, 2019
    TIME:   9:00am PT, 12:00pm ET
     
    Thienopyrazole derivatives have recently emerged as effective antitumoral agents with kinase inhibitory activity.  In this study, a novel thienopyrazole derivative with potent and selective in vitro cytotoxicity was identified in a high-throughput chemical library screening to identify novel anti-cancer drugs.  After 48 hours of exposure, compound Tpz-1 demonstrated potent and consistent cytotoxicity against a panel of human hematologic cells at nanomolar to low micromolar concentrations; an effect which was greatly diminished against the HS-27 non-cancerous foreskin fibroblast cell line.  Mechanistic analyses subsequently conducted against the CEM T-cell leukemia cell line revealed that Tpz-1 induces cell death via apoptosis and interferes with cell cycle progression in a dose-dependent manner.  These findings merit the further development of Tpz-1 as a novel therapeutic agent in the treatment of human hematologic cancers.
     
    In this webinar you will learn:
    • to investigate the mechanism, Tpz-1, through a series of apoptosis assays and a transcriptome analysis
    • Tpz-1 activity against leukemia and lymphoma cell lines and normal cell types.
     
     
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    Show Resources
    Attendees
    • See more
    Connect with us